Nectar Lifesciences Limited — Board Meeting, 14-08-2025: Outcome of Board Meeting

Nectar Lifesciences has announced a board meeting where it approved the financial results for the quarter, reporting a consolidated revenue of ₹280.66 Cr and a net loss of ₹63.23 Cr. Major strategic moves include the sale of its API and formulations business for ₹1270 Cr and the menthol business for ₹20 Cr. The company's 30th AGM is set for September 29, 2025, to consider the re-appointment of director Mr. Sanjiv Goyal and adoption of new Articles of Association. New Secretarial and Cost Auditors were also appointed.